Triheptanoin for children with PDC deficiency
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This trial tests an oil called triheptanoin for children with a rare genetic condition (PDCD) that affects how their bodies use energy. The study aims to see if triheptanoin can help improve their health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child must be 1 to 18 years old.
- Must have a confirmed genetic diagnosis of pyruvate dehydrogenase complex deficiency (PDCD).
- Must be followed by a metabolic doctor for their PDCD.
- Must already be on a ketogenic diet (a special high-fat, low-carb diet).
- Cannot be pregnant, breastfeeding, or in another treatment trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial provides access to an investigational drug called DCA (dichloroacetate) for people with pyruvate dehydrogenase complex deficiency, a rare genetic condition that affects energy production in the body. The goal is to offer a possible treatment option for those who have few other choices.
This study looks at how pyruvate dehydrogenase complex (PDC) deficiency affects people over time and what genes are involved. It mainly helps by building genetic and health data, which may improve future care and understanding of the condition.
This trial tests a medicine called sodium phenylbutyrate (ACER-001) to see if it helps people with MCADD, a genetic condition that affects how your body breaks down fats. If you have MCADD and the common gene change, you might be able to join.
This study tests if a medicine called Glycerol Phenylbutyrate (RAVICTI) is safe and helpful for children and young adults with a specific type of PDH deficiency, a rare genetic condition affecting energy use. If you qualify, you may get a new treatment option.
This program provides triheptanoin, a dietary oil that may help manage certain inherited metabolic conditions, to people who cannot join a clinical trial. If you qualify, you may access this treatment through your doctor.
This trial tests a new gene therapy treatment designed to help the body process certain amino acids better in infants with propionic acidemia. The therapy uses a modified virus to deliver a working copy of a faulty gene, potentially reducing dangerous acid buildups and hospital visits.
Hear when a new Pyruvate Dehydrogenase Complex Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.